Cancers最新文献

{"title":"HER2 Interactome Profiling Reveals MARCKS as a Candidate Marker Associated with Aggressive Breast Cancer.","authors":"Atsushi Yokoyama, Shun Sawatsubashi, Akiko Ebata, Yasuhiro Miki, Yuri Otsubo, Takashi Suzuki","doi":"10.3390/cancers17172882","DOIUrl":"https://doi.org/10.3390/cancers17172882","url":null,"abstract":"<p><p><b>Background/Objectives:</b> HER2, a critical diagnostic marker and therapeutic target in breast cancer, is a membrane receptor that forms diverse signaling complexes, the constituents of which have not been fully characterized in actual breast cancer tissues. <b>Methods:</b> In this study, we applied the Rapid Immunoprecipitation Mass Spectrometry of Endogenous Proteins (RIME) method, originally developed to explore transcription factor complexes, to identify the complexes formed by HER2 in HER2-positive breast cancer specimens. <b>Results:</b> Through our approach, we successfully identified multiple complex components, including MARCKS, a novel HER2-interacting partner, which we verified using both proximal ligation assay in cultured cells and immunohistochemistry in tissue sections. TCGA analysis further revealed that high MARCKS expression significantly correlates with ER negativity, as confirmed by multivariate analysis, suggesting its potential role as a prognostic indicator in aggressive breast cancer subtypes. <b>Conclusions:</b> These results demonstrate the capability of RIME to elucidate interactomes of membrane proteins such as HER2 in clinical tissue specimens. Furthermore, this study highlights its broader applicability beyond nuclear proteins, underscoring its potential for discovering novel prognostic and diagnostic clinical markers in diverse cancer types.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 17","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145052059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Emails to EMR: Implementing I-PASS Among Inpatient Palliative Care Clinicians at a Comprehensive Cancer Center-A Quality Improvement Initiative.","authors":"Jaya Amaram-Davila, Maria Franco Vega, Patricia Bramati, Holly Stewart, Monica Aceves, Shalini Dalal, Akhila Reddy, Ahsan Azhar, Suresh K Reddy, Diane C Bodurka, Marina George, Mohamed Ait Aiss, Eduardo Bruera","doi":"10.3390/cancers17172875","DOIUrl":"https://doi.org/10.3390/cancers17172875","url":null,"abstract":"<p><strong>Background: </strong>Inpatient palliative care consultation services operate with an interdisciplinary team, where effective handoffs are crucial for coordinated patient care. We aimed to replace encrypted email handoffs with a more concise and uniform handoff using I-PASS (illness severity, patient summary, action list, situational awareness, contingency planning, and synthesis by receiver) integrated within the electronic medical record (EMR). Aim and Measures: Within six months of launch, our goal was to achieve 90% I-PASS utilization for hospitalized acutely ill patients with cancer receiving palliative care consultation.</p><p><strong>Intervention: </strong>In January 2021, our quality improvement team, consisting of physicians, advanced practice providers, and trainees, began implementing I-PASS using the plan-do-study-act cycle. After providing training sessions for all palliative care clinicians, I-PASS went live on October 1, 2021. I-PASS utilization was tracked via random and monthly audits of EMRs. Through anonymous surveys, both pre- and post-implementation, we gathered clinician feedback and concerns about the handoff system. Survey responses were compared using the Mann-Whitney test.</p><p><strong>Outcomes: </strong>Within six months of implementation, the I-PASS utilization rate reached > 99%. The survey participation rates were 70% (45/64) and 82% (49/60) for the pre-and post-implementation periods, respectively. Respondents provided answers on one to five scale (mean, standard deviation, SD): lower accuracy with email (3.53, SD = 0.98) vs. I-PASS (4.20, SD = 0.83), <i>p</i> < 0.001; handoff lengthier with email (4.17, SD = 1.05) vs. I-PASS (2.1, SD = 1.15), <i>p</i> < 0.001; the time required was longer with email (3.0, SD = 1.22) vs. I-PASS (1.71, SD = 0.73), <i>p</i> < 0.001. Overall, respondents found I-PASS to be significantly better (4.69, SD = 0.58).</p><p><strong>Conclusion: </strong>I-PASS was fully adopted by the team, with nearly 100% utilization and strong clinician endorsement as an effective communication tool. Future efforts should focus on optimizing usability, particularly by educating clinicians on smartphone EMR access and enabling the timely and streamlined editing of I-PASS.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 17","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145052016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integration of Next-Generation Sequencing in Measurable Residual Disease Monitoring in Acute Myeloid Leukemia and Myelodysplastic Neoplasm.","authors":"Elena Crisà, Irene Dogliotti, Giuseppe Lia, Marco Cerrano, Ernesta Audisio, Giuseppe Lanzarone, Lucia Brunello, Daniela Caravelli, Fabrizio Carnevale Schianca, Enrico Berrino, Sara Erika Bellomo, Alice Bartolini, Ludovica Riera, Paola Francia di Celle, Gianluca Gaidano, Monia Lunghi, Luisa Giaccone, Benedetto Bruno","doi":"10.3390/cancers17172874","DOIUrl":"https://doi.org/10.3390/cancers17172874","url":null,"abstract":"<p><strong>Background/objectives: </strong>Recent evidence underscores the prognostic and classificatory relevance of somatic mutations in myelodysplastic neoplasms (MDSs) and acute myeloid leukemia (AML).</p><p><strong>Methods: </strong>This prospective study assessed gene mutation dynamics via next-generation sequencing (NGS) in 84 MDS/AML patients treated with intensive chemotherapy or hypomethylating agents plus venetoclax.</p><p><strong>Results: </strong>At diagnosis, 95% had somatic mutations detected by NGS, while only 29% had a measurable residual disease (MRD) marker with qPCRs. NGS at complete remission (CR) was performed in 56/71 patients who achieved CR; 59% had persisting mutations, mostly in DNMT3A, TET2, and ASXL1 (DTA mutations). Mutations' persistence in CR was linked to a shorter relapse-free survival (RFS; median 8 months vs. not reached, HR 4.41, 95% CI 1.69-11.49; <i>p</i> = 0.002) and overall survival (OS; 2-year OS: 51.5% vs. 88%, HR 4.02, 95% CI 1.39-11.65; <i>p</i> = 0.001). Combining NGS and multiparameter flow cytometry (MFC) for MRD detection, we divided patients into three groups with distinct RFS (NGS-/MFC-, NGS-/MFC+, or NGS+/MFC- and NGS+/MFC+), with double-negative patients displaying the best RFS (<i>p</i> < 0.001). In the multivariate analysis, NGS and MFC MRD+ were independent predictors of RFS.</p><p><strong>Conclusions: </strong>This real-world study confirms the added prognostic role of NGS in MRD detection on RFS, particularly when combined with MFC. This approach may improve risk stratification and guide treatment decisions.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 17","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145052061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endothelial Injury Following CAR-T Cell Immunotherapy for Hematological Malignancies.","authors":"Christos Demosthenous, Paschalis Evangelidis, Athanasios Gatsis, Ioannis Mitroulis, Sofia Vakalopoulou, Anna Vardi, Stefania Bountoura, Ioanna Sakellari, Eleni Gavriilaki","doi":"10.3390/cancers17172876","DOIUrl":"https://doi.org/10.3390/cancers17172876","url":null,"abstract":"<p><p>Chimeric antigen receptor-T (CAR-T) cell immunotherapy constitutes a cornerstone in the management of patients with relapsed/refractory B-cell lineage lymphoid malignancies. Toxicities such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and hematotoxicity (ICAHT) have been recognized in the post-infusion period. The initial interplay between CAR-T cells and tumor cells, followed by cytokine release and the bystander activation of the innate immunity cells, result in endothelial cell injury. In the current review, the ongoing research regarding endothelial injury in CAR-T cell recipients is summarized. Various markers of endothelial injury have been investigated in CAR-T cell recipients, including markers of complement activation, such as soluble C5b-9, endothelial dysfunction (angiopoietin-2, VCAM1, ICAM-1), inflammation, and thrombosis (von Willebrand antigen, ADAMTS13, thrombomodulin). The expression level of these endothelial injury markers has been identified as impaired in CAR-T cell recipients, not only when compared with healthy controls but also among patients with severe CRS/ICANS and those with mild toxicities or without toxicities. Furthermore, the Endothelial Activation and Stress Index (EASIX) and modified versions of this score, calculated in the pre- and early post-infusion period, seem to predict development of severe toxicities, ICAHT, and, thus, poor overall survival in CAR-T cell patients. More data concerning the role of these endothelial injury markers and clinical outcomes in CAR-T cell settings are essential.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 17","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145051892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Bone Health Considerations in Patients with Cancer.","authors":"Michelle Brennan, Tania Kalsi","doi":"10.3390/cancers17172878","DOIUrl":"https://doi.org/10.3390/cancers17172878","url":null,"abstract":"<p><p><b>Background:</b> Older adults with cancer are surviving longer due to earlier detection and more effective treatments for advanced stages. This population is at an elevated risk of osteoporosis due to age-related changes in bone density as well as the impact of cancer and cancer treatments on the skeletal system. <b>Main Body:</b> Cancer treatments are associated with increased bone loss and fracture risk via a variety of mechanisms. International guidelines recommend screening for cancer treatment-induced bone loss and provide treatment algorithms for pharmacological agents for those on hormonal therapy. There is a paucity of guidelines on bone health protection for those receiving intermittent glucocorticoid and newer immunotherapy regimes. <b>Results:</b> All patients receiving cancer treatment should undergo an individualised fracture risk assessment to optimise their bone health with regular review and reassessment of their risk profile. Dedicated bone health guidelines in cancer populations should be expanded to consider the impact of newer treatment modalities. All patients should receive education around non-pharmacological management and undergo a shared decision-making approach where there are indications for bone-targeted agents. <b>Conclusions:</b> Bone health assessment is an integral part of comprehensive geriatric assessment for older people with cancer. Strategies to minimise bone density loss and reduce fracture risk are an important consideration for cancer survivorship programmes for the majority of people and require a standardised approach.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 17","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145052008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune Checkpoint Inhibitors in Sinonasal Squamous Cell Carcinoma: A Retrospective Study and Literature Review.","authors":"Kosuke Terazawa, Masashi Kuroki, Ken Saijo, Tatsuhiko Yamada, Ryota Iinuma, Ryo Kawaura, Hiroshi Okuda, Kenichi Mori, Hirofumi Shibata, Ryo Utakata, Miki Umeda, Takenori Ogawa","doi":"10.3390/cancers17172872","DOIUrl":"https://doi.org/10.3390/cancers17172872","url":null,"abstract":"<p><p><b>Objective</b>: Sinonasal squamous cell carcinoma (SNSCC) is a rare and aggressive malignancy, with limited treatment strategies in the recurrent or metastatic cases. Although immune checkpoint inhibitors (ICIs) have shown efficacy in head and neck cancers (HNCs), clinical data specific to SNSCC are scarce. This study aimed to evaluate the therapeutic efficacy and prognosis of ICIs in patients with SNSCC. <b>Methods</b>: We conducted a retrospective review of 18 patients with pathologically confirmed SNSCC treated with nivolumab or pembrolizumab at Gifu University Hospital between May 2017 and December 2024. Treatment response was assessed using RECIST v1.1 criteria. Overall response rate (ORR) and disease control rate (DCR) were evaluated as treatment effects, and overall survival (OS) and progression-free survival (PFS) were evaluated as prognoses. Subgroup analyses were performed according to treatment regimen. <b>Results</b>: The ORR and DCR for all patients were 43.8% and 56.3%, respectively. Pembrolizumab-treated patients showed higher response rates (ORR: 66.7%; DCR: 83.3%) compared to those treated with nivolumab (ORR: 30%; DCR: 40%). Median OS and PFS were 21.5 and 7.9 months, respectively. Long-term durable responses exceeding two years were observed in several cases. Although pembrolizumab tended to result in better outcomes, no statistically significant difference was found between groups. Immune-related adverse events were infrequent and manageable. <b>Conclusions</b>: This study suggests that a subset of patients with SNSCC may benefit from ICI therapy, particularly in combination with chemotherapy. Despite the rarity of SNSCC, accumulating clinical evidence-including prospective studies-is essential to establish standardized treatment strategies for this disease.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 17","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145051943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improved Prognostic Stratification with the FIGO 2023 Staging System in Endometrial Cancer: Real-World Validation in 2969 Patients.","authors":"Jun-Hyeong Seo, Soo-Min Kim, Yoo-Young Lee, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Chel Hun Choi","doi":"10.3390/cancers17172871","DOIUrl":"https://doi.org/10.3390/cancers17172871","url":null,"abstract":"<p><strong>Background/objectives: </strong>To assess the impact of the 2023 FIGO staging revision on stage distribution, survival outcomes, and prognostic performance in endometrial cancer compared to the 2009 system.</p><p><strong>Methods: </strong>This retrospective cohort study analyzed 2969 patients with FIGO 2009 stage I-III endometrial cancer diagnosed at Samsung Medical Center (1994-2023). Patients were reclassified per the 2023 FIGO system. Stage migration, progression-free survival (PFS), and overall survival (OS) were evaluated. Prognostic performance was compared using the Akaike information criterion (AIC), Bayesian information criterion (BIC), concordance index (C-index), and area under the receiver operating characteristic curve (AUC).</p><p><strong>Results: </strong>Stage migration occurred in 20.2% of patients, with 98.3% involving upstaging from FIGO 2009 stage I, largely due to the inclusion of aggressive histology, p53 abnormality, and substantial lymphovascular space invasion (LVSI). The proportion of stage I tumors decreased from 81.5% to 65.2%, while stage II increased to 21.9%, including 14.8% newly classified as stage IIC. Patients remaining in stage I showed favorable outcomes (5-year PFS: 95.3%, OS: 98.5%), whereas those upstaged-especially to stage IIC-had significantly worse outcomes (5-year PFS: 76.5%, OS: 83.1%). Tumors with p53 abnormalities had poorer survival (PFS: 70.8%, OS: 76.6%). The 2023 FIGO system outperformed the 2009 system in prognostic discrimination across all metrics.</p><p><strong>Conclusions: </strong>The FIGO 2023 staging revision improves prognostic accuracy in endometrial cancer by integrating histopathologic and molecular risk factors. These refinements enhance risk stratification and may support more individualized treatment strategies.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 17","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145051942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Qualified Exercise Professionals in Medical Clearance for Exercise: Alberta Cancer Exercise Hybrid Effectiveness-Implementation Study.","authors":"Margaret L McNeely, Tanya Williamson, Shirin M Shallwani, Leslie Ternes, Christopher Sellar, Anil Abraham Joy, Harold Lau, Jacob Easaw, Adam Brown, Kerry S Courneya, S Nicole Culos-Reed","doi":"10.3390/cancers17172873","DOIUrl":"https://doi.org/10.3390/cancers17172873","url":null,"abstract":"<p><strong>Background: </strong>Current guidelines endorse the integration of exercise into cancer care. The diagnosis of cancer and its treatment, however, may introduce factors that make exercise engagement difficult, especially for individuals with advanced stages of disease. In this paper, we describe the baseline screening and triage process implemented for the Alberta Cancer Exercise (ACE) hybrid effectiveness-implementation study and share findings that highlight the multifaceted complexity of the process and the direct role of the clinical exercise physiologist (CEP).</p><p><strong>Methods: </strong>ACE was a hybrid effectiveness-implementation study examining the benefit of 12-week cancer-specific community-based exercise program. The ACE screening process was developed by integrating evidence-based guidelines with oncology rehabilitation expertise to ensure safe and standardized participation across cancer populations. The screening process involved four steps: (1) a pre-screen for high-risk cancers, (2) completion of a cancer-specific intake form and the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+), (3) a CEP-led interview to further evaluate cancer status, cancer-related symptoms and other health issues (performed in-person or by phone), and (4) a baseline fitness assessment that included measurement of vital signs.</p><p><strong>Results: </strong>A total of 2596 individuals registered and underwent prescreening for ACE with 2570 (86.6%) consenting to participate. After full screening including the baseline fitness testing, 209 participants (8.1%) were identified as requiring further medical clearance. Of these, 191 (91.4%) had either a high-risk cancer, metastatic disease or were in the palliative end-stage of cancer, and 161 (84.3%) reported cancer-related symptoms potentially affecting their ability to exercise. In total, 806 (31.4%) participants were triaged to CEP-supervised in-person programming, 1754 (68.2%) participants to ACE community programming, and 8 (0.3%) specifically to virtual programming (post-COVID-19 option).</p><p><strong>Conclusions: </strong>The findings highlight the complexity and challenges of the screening and triage process, and the value of a highly trained CEP-led iterative approach that included the application of clinical reasoning.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 17","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145051994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anticancer Effects of Ascorbic Acid: Not All Sides Fit All.","authors":"Uche O Arunsi, Jeremiah O Olugbami, Adegboyega K Oyelere","doi":"10.3390/cancers17172877","DOIUrl":"https://doi.org/10.3390/cancers17172877","url":null,"abstract":"<p><p><b>Background/Objectives:</b> Ascorbic acid (AA)is a micronutrient with concentration-dependent anticancer properties, acting either as a reactive oxygen species (ROS) scavenger or inducer. <b>Methods</b>: Conventional redox-based assays such as MTS/MTT often overestimate cell proliferation due to AA's interaction with tetrazolium salts, leading to increased formazan production. To overcome this limitation, we employed the Propidium Iodide Triton X-100 (PI/TX-100) assay to evaluate AA's cytotoxic effects across a diverse panel of cancer and normal cell lines, including prostate (22Rv1, C4-2B, DU-145, LNCaP), breast (MCF-7, MDA-MB-231, MDA-MB-453), lung (A549), liver (HepG2, SK-HEP-1, Huh7), and kidney (Vero) cells. <b>Results</b>: AA significantly suppressed cancer cell viability compared to normal cells (RWPE1 and Vero), with the strongest effects observed in hormone receptor-positive lines. The relative sensitivity to AA followed distinct patterns within each cancer type. Mechanistically, AA-induced cell death involved ROS generation, lipid peroxidation, cell cycle arrest, ferroptosis, apoptosis, and downregulation of pyruvate dehydrogenase kinase 1 (PDHK1). <b>Conclusions:</b> These findings further support the potential of AA as a selective anticancer agent and highlight the importance of assay choice in evaluating its therapeutic efficacy.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 17","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145051793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Proton-Pump Inhibitor on Survival in Chinese Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer Receiving Upfront Combinatorial Docetaxel Treatment.","authors":"Chris Ho-Ming Wong, Jamie Tsun Chiu, Ivan Ching-Ho Ko, David Ka-Wai Leung, Brian Siu, Cheuk-Kin Kevin Cheng, Yung-Yung Joycelyn Lim, Hiu Tung Mok, Chun-Fai Brian Kwok, Cheuk Yi Tang, Steven Chi-Ho Leung, Kang Liu, Peter Ka-Fung Chiu, Jeremy Yuen-Chun Teoh, Chi Fai Ng","doi":"10.3390/cancers17172879","DOIUrl":"https://doi.org/10.3390/cancers17172879","url":null,"abstract":"<p><p>Prostate cancer is the second most commonly found malignancy for men worldwide, with its prevalence increasing with age [...].</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 17","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145051958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}